The majority of patients with AD experience both cognitive decline and neuropsychiatric symptoms; however, the neuropsychiatric symptoms take a greater toll on family members and caregivers and impose a significant financial burden.
Masupiridine was shown in the current study to reduce both agitation/aggression and psychosis episodes in AD patients.
Patients with moderate AD were treated with masupiridine, and the effects were assessed using the 12-item neuropsychiatric inventory.
One hundred fifty-eight patients with moderate AD were enrolled in the study and treated as follows: placebo, n=57; masupiridine (50 mg), n=53; and masupiridine (100 mg), n=48.
Both doses of masupiridine decreased episodes of agitation/aggression (mild and severe forms) by week 13 compared to placebo, and the improvement was sustained through week 26. Similarly, both doses of masupiridine decreased psychosis episodes as early as week 4 of treatment.